• 1. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 2. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 3. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 4. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 5. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzopyrazoles Indazoles

Professional Introduction to Compound with CAS No. 885521-25-5 and Product Name: 3-Bromo-1H-indazol-4-amine

The compound with CAS number 885521-25-5 and the product name 3-Bromo-1H-indazol-4-amine represents a significant advancement in the field of pharmaceutical chemistry. This heterocyclic amine derivative has garnered considerable attention due to its unique structural properties and potential applications in drug development. The brominated indazole core serves as a versatile scaffold, enabling modifications that can enhance binding affinity and selectivity for various biological targets.

Recent research has highlighted the utility of 3-Bromo-1H-indazol-4-amine in the synthesis of novel therapeutic agents. Its bromine substituent allows for further functionalization via cross-coupling reactions, such as Suzuki-Miyaura and Buchwald-Hartwig couplings, which are pivotal in constructing complex molecular architectures. These reactions facilitate the integration of additional pharmacophores, thereby expanding the compound's pharmacological repertoire.

In the realm of medicinal chemistry, indazole derivatives have demonstrated promise in addressing a range of diseases, including cancer, infectious disorders, and neurological conditions. The incorporation of a bromine atom at the 3-position enhances reactivity while maintaining the inherent biological activity of the indazole ring. This balance is critical for designing molecules that can effectively interact with biological macromolecules, such as enzymes and receptors.

One of the most compelling aspects of 3-Bromo-1H-indazol-4-amine is its role as an intermediate in the development of kinase inhibitors. Kinases are key enzymes involved in signal transduction pathways, and their dysregulation is often associated with pathological states. By leveraging the structural flexibility of 3-Bromo-1H-indazol-4-amine, researchers have been able to design inhibitors that target specific kinases with high precision. For instance, modifications at the 4-amino position can fine-tune interactions with the ATP-binding site, improving drug efficacy.

Moreover, computational studies have indicated that 3-Bromo-1H-indazol-4-amine exhibits favorable physicochemical properties, including solubility and metabolic stability, which are essential for drug-like characteristics. These attributes make it an attractive candidate for further optimization into a lead compound. High-throughput screening (HTS) campaigns have been employed to identify derivatives with enhanced potency and reduced toxicity.

The synthesis of 3-Bromo-1H-indazol-4-amine typically involves multi-step organic transformations starting from commercially available precursors. Key steps include bromination at the 3-position of an indazole precursor followed by selective amination at the 4-position. Advances in synthetic methodologies have enabled more efficient and scalable production processes, reducing costs and improving yields.

In academic research, 3-Bromo-1H-indazol-4-amine has been employed in mechanistic studies to elucidate reaction pathways involving transition metal catalysis. Its reactivity under various conditions provides insights into how functional groups influence chemical transformations, contributing to the development of new synthetic strategies.

The pharmaceutical industry has also shown interest in 3-Bromo-1H-indazol-4-amine due to its potential as a building block for next-generation therapeutics. Collaborative efforts between academia and industry have led to innovative approaches in drug discovery, where this compound serves as a cornerstone in library design. Its versatility allows for rapid iteration in hit-to-lead optimization pipelines.

From a regulatory perspective, compounds like 3-Bromo-1H-indazol-4-amine must undergo rigorous testing to ensure safety and efficacy before entering clinical trials. Preclinical studies assess pharmacokinetic profiles, toxicity margins, and potential side effects. These evaluations are critical for determining whether a candidate progresses to human testing phases.

The future prospects of 3-Bromo-1H-indazol-4-amine are promising, with ongoing research exploring its applications in emerging therapeutic areas such as immunotherapy and gene editing. By integrating it into novel drug candidates, scientists aim to address unmet medical needs through innovative chemical solutions.

• 885520-95-6(3-Bromo-6-methyl-1H-indazol-4-amine)
• 52347-72-5(3-Bromo-1H-indazol-6-amine)
• 1092351-47-7(3-Bromo-1-methyl-1H-indazol-4-amine)
• 1000343-43-0(5-Amino-3-bromo-6-methyl (1H)Indazole)
• 885518-53-6(4-Bromo-1H-indazol-6-amine)
• 40598-94-5(3-Bromo-1H-indazole)
• 316810-90-9(3-Bromo-1H-indazol-7-amine)
• 478837-59-1(3-Bromo-1H-indazol-5-amine)
• 885518-50-3(6-Bromo-1H-indazol-4-amine)
• 885519-95-9(4-Amino-3-bromo-6-chloro (1H)indazole)